RIPK1 and lymphoma: Of the 36 cases examined, positive expression of RIP1 was identified in 2/3 cases (67%) of adenocarcinoma with pathological grade I, 7/10 cases (70%) of adenocarcinoma with pathological grade I–II, 7/9 cases (78%) of adenocarcinoma with pathological grade II, 3/3 cases (100%) of adenocarcinoma with pathological grade II–III, 5/5 cases (100%) of adenocarcinoma with pathological grade III, 2/2 cases (100%) of papillary adenocarcinoma, 3/4 cases (75%) of mucinous adenocarcinoma, 1/1 cases (100%) of stromal tumor and 1/1 cases (100%) of lymphoma.